Qiagen is a diagnostics & research business based in the US. Qiagen shares (QGEN) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $43.65 – an increase of 0.92% over the previous week. Qiagen employs 5,800 staff and has a trailing 12-month revenue of around $2 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $43.65 |
|---|---|
| 52-week range | $39.03 - $47.44 |
| 50-day moving average | $43.32 |
| 200-day moving average | $43.39 |
| Wall St. target price | $50.59 |
| PE ratio | 97.2222 |
| Dividend yield | $0 (2.94%) |
| Earnings per share (TTM) | $0.45 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $43.43 from 2024-11-29
| 1 week (2024-11-25) | 0.42% |
|---|---|
| 1 month (2024-11-01) | 0.81% |
| 3 months (2024-08-30) | -4.99% |
| 6 months (2024-05-31) | 0.39% |
| 1 year (2023-12-01) | 1.63% |
|---|---|
| 2 years (2022-12-02) | -13.81% |
| 3 years (2021-12-02) | 54.6028 |
| 5 years (2019-12-02) | 0.69% |
Valuing Qiagen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Qiagen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Qiagen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 97x. In other words, Qiagen shares trade at around 97x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Qiagen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0001. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Qiagen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Qiagen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $669.6 million.
The EBITDA is a measure of a Qiagen's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2 billion |
|---|---|
| Operating margin TTM | 25.79% |
| Gross profit TTM | $1.4 billion |
| Return on assets TTM | 4.84% |
| Return on equity TTM | 2.57% |
| Profit margin | 4.73% |
| Book value | $15.88 |
| Market Capitalization | $9.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 61.97% of net profits
Recently Qiagen has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Qiagen shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Qiagen's case, that would currently equate to about $0 per share.
Qiagen's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Qiagen's most recent dividend payout was on 29 January 2024. The latest dividend was paid out to all shareholders who bought their shares by 29 January 2024 (the "ex-dividend date").
Qiagen's shares were split on a 962:1000 basis on 24 January 2017 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 962 shares. This wouldn't directly have changed the overall worth of your Qiagen shares – just the quantity. However, indirectly, the new 4% higher share price could have impacted the market appetite for Qiagen shares which in turn could have impacted Qiagen's share price.
Over the last 12 months, Qiagen's shares have ranged in value from as little as $39.03 up to $47.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Qiagen's is 0.404. This would suggest that Qiagen's shares are less volatile than average (for this exchange).
Qiagen N. V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.